KR860002553A - 마크로폴리사이클 희토류 복합체의 제조방법 - Google Patents

마크로폴리사이클 희토류 복합체의 제조방법 Download PDF

Info

Publication number
KR860002553A
KR860002553A KR1019850007109A KR850007109A KR860002553A KR 860002553 A KR860002553 A KR 860002553A KR 1019850007109 A KR1019850007109 A KR 1019850007109A KR 850007109 A KR850007109 A KR 850007109A KR 860002553 A KR860002553 A KR 860002553A
Authority
KR
South Korea
Prior art keywords
bis
phenanthroline
radical
macropolycycle
bipyridine
Prior art date
Application number
KR1019850007109A
Other languages
English (en)
Other versions
KR930008210B1 (ko
Inventor
마띠스 줴라르 (외 1)
Original Assignee
삐에르 쇼무조
코미싸리아따 레네르지 아토미끄
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삐에르 쇼무조, 코미싸리아따 레네르지 아토미끄 filed Critical 삐에르 쇼무조
Publication of KR860002553A publication Critical patent/KR860002553A/ko
Application granted granted Critical
Publication of KR930008210B1 publication Critical patent/KR930008210B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
    • C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/40—Rare earth chelates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음

Description

마크로폴리사이클 희토류 복합체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 희토류이온의 형광을 향상하는 방법에 있어서, 다음식의 마크로폴리사이클 화합물과 하나 이상의 회토류 이온을 착화하고 그 화합물의 공여단위를 여기시킴을 특징으로 하는 방법:
    상기식에서, Z는 3가 또는 4가 원자이고, R은 빈항이거나 또는 수소, 히드록실기, 아미노기 또는 탄화수소 라디칼을 나타내며, 2가 라디칼와는 하나 이상의 헤테로 원자를 임의로 함유하는 헤테로 마크로사이클에 의하여 임의로 개입되는 서로 독립적인 탄화수소체인이다. 또한 라디칼또는의 적어도 하나는 하나이상의 분자단위를 함유하거나 또는 기본적으로 한 분자단위로 되어 있음, 분자단위는 착화된 회토류 이온의 발광준위보다 더 큰 삼중항에너지를 보유함.
  2. 마크로폴리사이클 회토류 복합체의 제조방법에 있어서, 다음 식의 마크로폴리사이클 화합물과 하나 이상의 회토류 염을 반응시킴을 특징으로 하는 방법:
    상기식에서, Z는 3가 또는 4가 원자이고, R은 빈항이거나 또는 수소, 히드록실기, 아미노기 또는 탄화수소 라디칼을 나타내며, 2가 라디칼와는 하나 이상의 헤테로 원자를 임으로 함유하고 헤테로 마크로사이클에 의하여 임의로 개입되는 서로 독립적인 탄화수소체인이다. 또한 라디칼또는의 적어도 하나는 하나이상의 분자단위를 함유하거나 또는 기본적으로 한 분자단위로 되어 있음. 분자단위는 착화된 회토류 이온의 발광준위보다 더 큰 삼중항에너지를 보유함. 단서로서, 만일 회토류염이 유로퓸 도는 테르븀염이라면 Z는 질소 R은 H또는 NH2. ⓐ는 (CH2)2-O-C6H3R-O-(CH2)2-, ⓑ와 ⓒ는 동시에 같지는 않고 각각 라디칼 -(CH2)2-O-(CH2)2-와 라디칼 -(CH2)2-O-(CH2)2-O-(CH2)2-의 하나이고, R은 H 또는 NH2임.
  3. 제2항에 있어서, 탄화수소체인 에톡실화 또는 폴리에톡실화된 체인임을 특징으로 하는 방법.
  4. 제2 또는 3항에 있어서, 회토류 이온이 유로퓸, 테르븀, 사마륨가 디스프로슘으로 된 기로부터 선택됨을 특징으로 하는 방법.
  5. 제2항에 있어서, 에너지공여단위가 580nm 미만의 인광파장을 가짐을 특징으로 하는 방법.
  6. 제2항에 있어서, 분자단위가 펜안트롤린, 안트라센, 벤젠, 나프탈렌, 비페닐과 테르페닐, 아조벤젠, 아조피리딘, 피리딘, 비피리딘류, 그리고 비스퀴놀린류, 그리고 다음 식의 화합물로 되어있는 기로부터 선택됨을 특징으로 하는 방법:
    -C2H4-X1-C6H4-X2-C2H4- ; -C2H4-X1-CH2-C6H4-CH2-X2-C2H4-;
    상기식에서 X1과 X2는 동일하거나 다를 수있는데 산소, 질소 또는 황을 나타냄.
    상기식에서, X는 산소 또는 수소임.
  7. 제2항에 있어서 회토류 이온이 유로퓸 또는 테르븀이고 다음 마크로폴리사이클 화합물중 하나와 착화됨을 특징으로 하는 방법:(22)안트라센; (22)펜안트롤린; (22)펜안트롤린아미드; 22)안트라센아미드; (22)비이소퀴놀린; (22)비페닐-비피리딘; (22)비피리딘; (22);피리딘아미드, 트리스-비피리딘마크로폴리사이클, 펜안트롤린-비스-비피리딘트리스-펜안트롤린, 비스 이소퀴놀린 비스 비피리딘과 비스 비피리딘-디페닐비피리딘 마크로폴리사이클.
  8. 다음식을 갖는 마크로폴리사이클 화합물의 제조방법에 있어서:
    Z는 3가 또는 4가 원자이고, R은 빈항이거나 또는 수소, 히드록실기, 아미노기 또는 탄화수소 라디칼을 나타내며, 2가 라디칼와는 하나 이상의 헤테로 원자를 임으로 함유하는 헤테로 마크로사이클에 의하여 임의로 개입되는 서로 독립적인 탄화수소체인이고, 또한 라디칼또는 ⓒ의 적어도 하나는 하나이상의 분자단위를 함유하거나 또는 기본적으로 한 분자단위로 되어 있고, 분자단위는 착화된 회토류 이온의 발광준위보다 더 큰 삼중항에너지를 보유하고, 펜안트롤린, 안트라센 및 비피리딘류 및 이소퀴놀린류로 되어 있는 기로부터 선택되는데 Z가 질소, ⓐ는 다음 식중의 하나에 해당하고:
    ⓑ와 ⓒ는 동시에 -(CH2)2-O-(CH2)2-O-(CH2)2-가 아니라는 조건하에서, 라디칼 ⓐ,ⓑ 또는 ⓒ의 하나를 갖고 치환될 수 있는 말단기를 갖거나 또는 쉽게 제거될 수 있는 라디칼을 함유하는 각각의 화합물을 축합함을 특징으로 하는 방법.
  9. 제8항에 있어서, 식I의 Z가질소이고 ⓐ와 ⓑ가 폴리에톡실화된 체인일때, 1)두개의 폴리에톡실화된 체인으로 되어 있는 질소마크로사이클과 전술한 분자단위를 함유하고, 쪼갤 수 있는 말단기(예를들면 할로게노기)를 갖는 탄화수소체인을 반응시키고, 2)이렇게 얻은 염을 자유마크로폴리사이클 화합물로 임의 변환함을 특징으로 하는 방법.
  10. 제8또는 9항에 있어서, 질소마크로사이클이 다음 1)의 마크로사이클들 중에서 선택되고 탄화수소 체인이 다음 2)의 화합물들중에서 선택됨을 특징으로 하는 방법:
    1)C(22), 비스-비피리딘과 비스-펜안트롤린.
    2)-2,9-디브로모메틸-1,10-펜안트롤린,-2,9-디클로로카르보닐-1,10-펜안트롤린, -6,6′-비스-브로모메틸-2,2′-비피리딘, -2,9-비스-브로모메틸-1,10-펜안트롤린, 1,1′-비스-브로모메틸-3,3-비이소퀴놀린,-6,6′-비스-브로모메틸-4,4′-디페닐-2,2′-비피리딘, -9,10-비스-클로로카르보닐메틸-안트라센.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850007109A 1984-09-26 1985-09-26 마크로폴리사이클 희토류 복합체의 제조방법 KR930008210B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8414799A FR2570703B1 (fr) 1984-09-26 1984-09-26 Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
FR8414799 1984-09-26

Publications (2)

Publication Number Publication Date
KR860002553A true KR860002553A (ko) 1986-04-26
KR930008210B1 KR930008210B1 (ko) 1993-08-26

Family

ID=9308106

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850007109A KR930008210B1 (ko) 1984-09-26 1985-09-26 마크로폴리사이클 희토류 복합체의 제조방법

Country Status (9)

Country Link
US (1) US4927923A (ko)
EP (1) EP0180492B1 (ko)
JP (3) JPH0655741B2 (ko)
KR (1) KR930008210B1 (ko)
AT (1) ATE90084T1 (ko)
CA (1) CA1329593C (ko)
DE (1) DE3587380T2 (ko)
ES (3) ES8706792A1 (ko)
FR (1) FR2570703B1 (ko)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220012A (en) * 1984-09-26 1993-06-15 Compagnie Oris Industrie Sa Macropolycyclic rare earth complexes and application as fluorescent tracers
SE454781B (sv) * 1986-10-17 1988-05-30 Wallac Oy Hybridiseringsforfarande for detektion av polynukleotidsekvens
FR2624862B1 (fr) * 1987-12-18 1990-06-08 Oris Ind Cryptates de terres rares, procedes d'obtention, intermediaires de synthese et application a titre de marqueurs fluorescents
US5162508A (en) * 1987-12-18 1992-11-10 Compagnie Oris Industrie Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers
US5134232A (en) * 1988-11-14 1992-07-28 The Regents Of The University Of California Fluorescent indicator dyes for alkali metal cations
US5094759A (en) * 1989-03-17 1992-03-10 The University Of Southern Mississippi Method of water treatment using 2,6-substituted aminopyridines and polymer derived therefrom
US5216134A (en) * 1989-10-23 1993-06-01 Wallac Oy Spectrofluorometric method and compounds that are of value for the method
FR2664699B1 (fr) * 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
JPH06505795A (ja) * 1990-09-27 1994-06-30 リサーチ・コーポレイション・テクノロジーズ キレート化剤
EP0493745A1 (en) * 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
FR2680787B1 (fr) * 1991-08-30 1994-11-04 Cis Bio Int Complexes macrocycliques de terres rares et leur utilisation pour reduire les interferences dans un dosage par fluorescence.
DE69131206T2 (de) * 1991-12-05 2000-01-05 Wallac Oy Lumineszierende lanthanidenchelate
US5417959A (en) * 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
WO1995020353A1 (en) * 1994-01-28 1995-08-03 Mallinckrodt Medical, Inc. Functionalized aza-bimacrocyclic ligands for imaging applications
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US5792330A (en) * 1995-05-31 1998-08-11 Board Of Regents, The University Of Texas System Lanthanide metal cations for concurrent detection and separation in capillary electrophoresis
FR2768817B1 (fr) * 1997-09-19 1999-12-10 Cis Bio Int Methode homogene pour la detection et/ou la determination de l'activite phosphorylante d'un materiel biologique
FR2769315B1 (fr) * 1997-10-03 2001-06-08 Cis Bio Int Conjugues fluorescents de nucleosides ou de nucleotides, leur procede de preparation et leur utilisation
CA2324648C (en) 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
EP1925320A3 (en) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
US7109315B2 (en) * 2000-03-15 2006-09-19 Bruce J. Bryan Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
FR2809817B1 (fr) 2000-06-02 2003-08-15 Cis Bio Int Procede de detection de presence d'un liquide dans un melange
FR2810406B1 (fr) * 2000-06-15 2002-09-20 Cis Bio Int Nouveaux cryptates de terre rare peu sensibles a l'extinction de fluorescence
WO2004039962A2 (en) * 2002-10-30 2004-05-13 Pointilliste, Inc. Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
EP1597577A4 (en) * 2003-02-10 2007-02-21 Pointilliste Inc SELF-ARRANGING ARRAYS AND ITS APPLICATION
US7018851B2 (en) * 2003-02-13 2006-03-28 Innotrac Diagnostics Oy Biospecific binding reactants labeled with new luminescent lanthanide chelates and their use
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
JP2007505315A (ja) * 2003-09-12 2007-03-08 インヴィトロジェン コーポレーション 多重結合および活性アッセイ
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
CA2545066C (en) * 2003-11-07 2014-01-21 Newport Instruments A reagent system and method for modifying the luminescence of lanthanide(iii) macrocyclic complexes
WO2005067980A2 (en) * 2004-01-12 2005-07-28 Pointilliste, Inc. Design of therapeutics and therapeutics
CA2575675A1 (en) * 2004-07-30 2006-03-09 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
FR2878850B1 (fr) * 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
DE102005020384A1 (de) * 2005-05-02 2006-11-09 Therainvention Gmbh Spektroskopisches Verfahren zum Nachweis von Analyten
JP4559922B2 (ja) * 2005-06-21 2010-10-13 株式会社東芝 蛍光性錯体及びそれを用いた照明装置
FR2890174B1 (fr) * 2005-08-30 2009-04-24 Cis Bio Internat Sa Procede pour la mise en evidence d'un processus biologique par mesure d'un fret
FR2890446B1 (fr) 2005-09-05 2008-04-18 Cis Bio Internat Sa Methode de detection d'interaction intracellulaire entre bio-molecules
EP2221385A3 (en) 2005-10-28 2010-12-01 Life Technologies Corporation Deubiquination assays
US7482444B2 (en) * 2006-03-13 2009-01-27 Wallac Oy Terminating substrates for DNA polymerases
DE102006021406B4 (de) 2006-05-08 2008-08-07 B.R.A.H.M.S Aktiengesellschaft In vitro Verfahren zur Früherkennung von arznei- und suchtmittelinduzierten Leberschäden und zur Erkennung der bereits erreichten Stufe der Leberschädigung
WO2008020113A1 (en) 2006-08-18 2008-02-21 Abacus Diagnostica Oy Luminescent lanthanide labelling reagents and their use
WO2008066187A1 (fr) * 2006-11-27 2008-06-05 Sumitomo Chemical Company, Limited Complexe polynucléaire
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
DE102007022367A1 (de) 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
CN102124346B (zh) * 2008-07-16 2014-01-15 雷迪奥米特医学公司 凝血酶底物和测定样本中生物活性凝血酶水平的测定法
FR2934684B1 (fr) 2008-07-31 2012-11-16 Cis Bio Int Methode de detection de l'internalisation de proteines membranaires.
FR2936245B1 (fr) 2008-09-23 2012-07-06 Cis Bio Int Nouveaux substrats d'o6-alkylguanine-adn alkyltransferase et ses mutants.
FR2940286B1 (fr) 2008-12-19 2011-04-08 Cis Bio Int Nouveaux cryptates de terres rares comportant un motif tetraazatriphenylene
FI20090100A0 (fi) 2009-03-16 2009-03-16 Wallac Oy Biotinidaasimääritys
CA2759885A1 (fr) 2009-04-30 2010-11-04 Etienne Doumazane Procede de detection de composes modulateurs de dimeres de proteines membranaires a domaine vft
FR2949156B1 (fr) 2009-08-13 2016-04-15 Cis-Bio Int Methode de determination de la liaison d'un compose donne a un recepteur membranaire
FR2977674B1 (fr) 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
FR2978149B1 (fr) 2011-07-18 2014-01-10 Cisbio Bioassays Nouveaux agents complexants et complexes de lanthanide correspondant, et leur utilisation comme marqueurs luminescents
FR2980271B1 (fr) 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
WO2013042120A2 (en) 2011-09-19 2013-03-28 Proteologics Ltd Synthetic ubiquitins and use thereof in drug screening assays
WO2013124544A1 (fr) 2012-02-22 2013-08-29 Cisbio Bioassays Procede de normalisation de la luminescence emise par un milieu de mesure.
FR2988174B1 (fr) 2012-03-19 2014-04-25 Cisbio Bioassays Procede de determination de la capacite d'un anticorps a maintenir des cellules a proximite l'une de l'autre
WO2014136115A1 (en) 2013-03-07 2014-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Non-selfabsorbing luminescent solar concentrator
FR3004189B1 (fr) 2013-04-04 2015-09-04 Ecole Norm Superieure Lyon Complexes de lanthanide comprenant au moins deux groupes betaines, utiles comme marqueurs luminescents
FR3032797B1 (fr) 2015-02-13 2017-03-03 Cisbio Bioassays Procede de quantification d'une proteine d'interet presente dans un echantillon biologique
US20180348235A1 (en) 2015-11-27 2018-12-06 B.R.A.H.M.S Gmbh MR-proADM as marker for the extracellular volume status of a subject
FR3045053B1 (fr) 2015-12-09 2018-01-05 Cisbio Bioassays Agents complexants hydrosolubles a base de triazapyridinophane et complexes de lanthanide fluorescents correspondants
CN109072280B (zh) 2016-01-21 2022-10-14 赛录科试诊断公司 用于快速抗微生物剂敏感性测试的方法
US9834808B2 (en) 2016-01-21 2017-12-05 SeLux Diagnostics, Inc. Methods for rapid antibiotic susceptibility testing
EP3497450A1 (en) 2016-08-09 2019-06-19 B.R.A.H.M.S GmbH Histones and/or proadm as markers indicating organ dysfunction
RU2765212C2 (ru) 2016-08-09 2022-01-26 Б.Р.А.Х.М.С. Гмбх Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
CA3048213A1 (en) 2016-12-23 2018-06-28 Eric Stern Methods for improved rapid antimicrobial susceptibility testing
CN110431425B (zh) 2017-02-02 2023-06-27 B.R.A.H.M.S 有限公司 proADM作为指示不良事件的标志物
US20200225248A1 (en) 2017-05-31 2020-07-16 B.R.A.H.M.S Gmbh Mmp-8 as a marker for identifying infectious disease
FR3067349B1 (fr) 2017-06-12 2020-12-04 Cisbio Bioassays Nouveaux agents mono et di-antennes complexants hydrosolubles et complexes de lanthanide correspondants
FR3067712B1 (fr) 2017-06-14 2019-08-02 Cisbio Bioassays Nouveaux agents complexants de type trimethoxyphenyl pyridine hydrosolubles et complexes de lanthanide correspondants
FR3069644A1 (fr) 2017-07-28 2019-02-01 Cisbio Bioassays Methode pour mesurer la modulation de l'activation d'un recepteur couple a une proteine g
BR112020004138A2 (pt) 2017-09-13 2020-09-08 B.R.A.H.M.S Gmbh pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico
WO2019053117A1 (en) 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh PCT AND PRO-ADM USED AS CONTROL MARKERS IN ANTIBIOTIC TREATMENT
EP3502691A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
US11327082B2 (en) 2017-09-13 2022-05-10 B.R.A.H.M.S Gmbh Proadrenomedullin as a marker for abnormal platelet levels
US20200271666A1 (en) 2017-09-13 2020-08-27 B.R.A.H.M.S Gmbh Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
US20210109118A1 (en) 2017-12-20 2021-04-15 B.R.A.H.M.S Gmbh Antibiotic therapy guidance based on pro-adm
EP3729082A1 (en) 2017-12-20 2020-10-28 B.R.A.H.M.S GmbH Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
ES2898929T3 (es) 2017-12-21 2022-03-09 H Lundbeck As Diagnóstico y tratamiento de alfa-sinucleinopatías
EP3578989A1 (en) 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm for prognosis of trauma-related complications in polytrauma patients
FR3084365B1 (fr) 2018-07-27 2020-10-23 Cisbio Bioassays Anticorps a domaine unique qui se lient a la proteine g alpha
EP3608673A1 (en) 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
JP2022520931A (ja) 2019-01-28 2022-04-04 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー 夜尿症の患者の治療応答を予測する方法
FR3092172B1 (fr) 2019-01-30 2021-02-12 Cisbio Bioassays Méthode pour mesurer la modulation de l’activation d’un récepteur couplé à une protéine G avec des analogues du GTP
EP3928099A1 (en) 2019-02-21 2021-12-29 B.R.A.H.M.S GmbH Diagnosis or prognosis of postsurgical adverse events
EP3715851A1 (en) 2019-03-29 2020-09-30 B.R.A.H.M.S GmbH Prescription of remote patient management based on biomarkers
AU2020253042A1 (en) 2019-03-29 2021-06-17 B.R.A.H.M.S Gmbh Prescription of remote patient management based on biomarkers
US11845976B2 (en) 2019-08-27 2023-12-19 SeLux Diagnostics, Inc. Systems and methods for performing antimicrobial susceptibility testing
WO2021204770A1 (en) 2020-04-06 2021-10-14 B.R.A.H.M.S Gmbh Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (sars)
CN115136009A (zh) 2020-04-09 2022-09-30 B.R.A.H.M.S有限公司 用于呼吸道感染诊断的生物标志物
CA3239310A1 (en) 2021-12-08 2023-06-15 Emmanuel BUJOLD Biomarkers for prognosis of early onset preeclampsia
WO2023110832A1 (en) 2021-12-13 2023-06-22 UNIVERSITé LAVAL Biomarkers for the prediction of preterm birth
WO2024121392A1 (en) 2022-12-08 2024-06-13 B.R.A.H.M.S Gmbh Multiple sflt-1 measurements for prognosis of early onset preeclampsia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888877A (en) * 1969-06-11 1975-06-10 Schering Corp Macrocyclic compounds and complexes thereof
CA966127A (en) * 1970-05-12 1975-04-15 Marilyn H. Bromels Macrocyclic hetero imine complexing agents
US3847949A (en) * 1970-05-12 1974-11-12 Du Pont Macrocyclic hetero imine complexing agents
US3966766A (en) * 1973-03-26 1976-06-29 Schering Corporation Monocyclic macrocyclic compounds and complexes thereof
US4156683A (en) * 1973-03-26 1979-05-29 Schering Corporation Complexes of macrocyclic compounds
US4058732A (en) * 1975-06-30 1977-11-15 Analytical Radiation Corporation Method and apparatus for improved analytical fluorescent spectroscopy
SE428332B (sv) * 1979-03-08 1983-06-20 Wallac Oy Forfarande for fluorescensspektroskopisk bestemning av biologiskt aktivt emne, sasom hapten, antikropp eller antigen
US4352751A (en) * 1979-09-10 1982-10-05 Analytical Radiation Corporation Species-linked diamine triacetic acids and their chelates
CA1205028A (en) * 1981-07-01 1986-05-27 Jerald C. Hinshaw Fluorescent chelates and labeled specific binding reagents prepared therefrom
DE3202779A1 (de) * 1982-01-28 1983-08-04 Merck Patent Gmbh, 6100 Darmstadt Kaliumreagens und verfahren zur bestimmung von kaliumionen
US4631119A (en) * 1983-11-23 1986-12-23 W. R. Grace & Co. Reversible, electrochemically-switched lariat ethers
US4734376A (en) * 1985-02-04 1988-03-29 The President & Trustees Of The Miami University Process for the spectrophotometric measurement of lithium ion employing a chromogenic aza-12-crown-4- ether
US4659815A (en) * 1985-02-04 1987-04-21 The President And Trustees Of The Miami University Chromogenic aza-12-crown-4 ethers and method of using same for the detection of lithium
GB8528804D0 (en) * 1985-11-22 1985-12-24 Amersham Int Plc Compounds

Also Published As

Publication number Publication date
KR930008210B1 (ko) 1993-08-26
US4927923A (en) 1990-05-22
ES557485A0 (es) 1988-02-16
JPH06199858A (ja) 1994-07-19
DE3587380D1 (ko) 1993-07-08
FR2570703B1 (fr) 1988-07-08
JPH0714935B2 (ja) 1995-02-22
CA1329593C (en) 1994-05-17
FR2570703A1 (fr) 1986-03-28
JPH0655741B2 (ja) 1994-07-27
ES8801938A1 (es) 1988-03-01
ES557486A0 (es) 1988-03-01
ATE90084T1 (de) 1993-06-15
JPS6187680A (ja) 1986-05-06
JPH0715471B2 (ja) 1995-02-22
ES8706792A1 (es) 1987-07-01
ES8801695A1 (es) 1988-02-16
JPH06184151A (ja) 1994-07-05
EP0180492A1 (fr) 1986-05-07
ES547294A0 (es) 1987-07-01
DE3587380T2 (de) 1994-01-05
EP0180492B1 (fr) 1993-06-02

Similar Documents

Publication Publication Date Title
KR860002553A (ko) 마크로폴리사이클 희토류 복합체의 제조방법
Faulkner et al. Magnetic field effects on anthracene triplet-triplet annihilation in fluid solutions
AU3408989A (en) Macrocyclic amine complexes for ligand extraction and generation
FR2680787B1 (fr) Complexes macrocycliques de terres rares et leur utilisation pour reduire les interferences dans un dosage par fluorescence.
ATE329923T1 (de) Phosphite
MY116852A (en) Phosphazenium salt and preparation process thereof, and process for producing poly (alkylene oxide)
KR840005445A (ko) 크산린 유도체의 제조방법
KR850004609A (ko) 비등방성 화합물을 포함하는 액정조성물
KR870002293A (ko) 수 전도시스템용 금속부식억제 조성물
KR830005217A (ko) 이미다조 피리딘의 제조방법
KR850003147A (ko) 인-개질된 폴리에스테르 카보네이트 수지의 제조방법
Saraceno et al. Electronic properties of phosphazene substituents on ferrocene
IE45090L (en) N-phosphonomethylene - aminoalkane phosphonic acids.
AU6830598A (en) Organopolysiloxanes whith dye residues
MY120565A (en) Phosphine compound
Balch Ligand-exchange reactions of bis-1, 2-dithiolene complexes
Berthon et al. Synthesis, electrochemical and spectroscopic properties of pendant hydroquinone-and quinone-substituted polypyridyl ruthenium (II) complexes
MY114850A (en) Process for preparing an organic compound from an oxirane-containing compound in the presence of a tris (triaminophosphoranylideneamino) phosphine oxide
Merschrod et al. Bonding in an Unusual Nickel Carbide
DE3687570D1 (de) Aromatisches polymer und verfahren zu dessen herstellung.
ATE222258T1 (de) Herstellung von phosphin-liganden
DE69001603T2 (de) Verfahren zum herstellen von perfluoroalkylbromiden.
JPS56120729A (en) Polyphenylene ether having allyl group at side chain
Bernardi et al. The 1, 3-dimethyltriazaallyl radical
KR880010016A (ko) 촉매 시스템, 및 축합 중합체의 합성 방법

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050720

Year of fee payment: 13

EXPY Expiration of term